
Opioid Withdrawal Syndrome- - Pipeline Insight, 2025
Description
DelveInsight’s, “Opioid Withdrawal Syndrome – Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Opioid Withdrawal Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Opioid Withdrawal Syndrome: Overview
Opioid Withdrawal Syndrome is a life-threatening condition resulting from opioid dependence. Opioids are a group of drugs used for the management of severe pain. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Common signs of opioid withdrawal include: anxiety, goosebumps, restlessness, insomnia, yawning, runny nose, watery eyes, fever, nausea, vomiting, diarrhea and others. The principal site in the brain that triggers the onset of Opioid Withdrawal Syndrome is the locus coeruleus at the base of the brain. At present, the approaches to treat the condition present in Opioid Withdrawal Syndrome treatment market are gradual cessation of an opioid agonist (methadone); Short-term use of a partial mu-opioid agonist (buprenorphine) and detoxification using opioid antagonists (naltrexone and naloxone).
""Opioid Withdrawal Syndrome - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Withdrawal Syndrome pipeline landscape is provided which includes the disease overview and Opioid Withdrawal Syndrome treatment guidelines. The assessment part of the report embraces, in depth Opioid Withdrawal Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Withdrawal Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Opioid Withdrawal Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Withdrawal Syndrome Emerging Drugs
Further product details are provided in the report……..
Opioid Withdrawal Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Withdrawal Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Opioid Withdrawal Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Withdrawal Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Withdrawal Syndrome drugs.
Opioid Withdrawal Syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Opioid Withdrawal Syndrome: Overview
Opioid Withdrawal Syndrome is a life-threatening condition resulting from opioid dependence. Opioids are a group of drugs used for the management of severe pain. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Common signs of opioid withdrawal include: anxiety, goosebumps, restlessness, insomnia, yawning, runny nose, watery eyes, fever, nausea, vomiting, diarrhea and others. The principal site in the brain that triggers the onset of Opioid Withdrawal Syndrome is the locus coeruleus at the base of the brain. At present, the approaches to treat the condition present in Opioid Withdrawal Syndrome treatment market are gradual cessation of an opioid agonist (methadone); Short-term use of a partial mu-opioid agonist (buprenorphine) and detoxification using opioid antagonists (naltrexone and naloxone).
""Opioid Withdrawal Syndrome - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Withdrawal Syndrome pipeline landscape is provided which includes the disease overview and Opioid Withdrawal Syndrome treatment guidelines. The assessment part of the report embraces, in depth Opioid Withdrawal Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Withdrawal Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Withdrawal Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Withdrawal Syndrome.
This segment of the Opioid Withdrawal Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Withdrawal Syndrome Emerging Drugs
- CHF-6563: Chiesi Farmaceutici S.p.A.
- BXCL501: BioXcel Therapeutics
Further product details are provided in the report……..
Opioid Withdrawal Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Withdrawal Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Opioid Withdrawal Syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Sublingual
- Topical
- Product type
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Opioid Withdrawal Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Withdrawal Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Withdrawal Syndrome drugs.
Opioid Withdrawal Syndrome Report Insights
- Opioid Withdrawal Syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Opioid Withdrawal Syndrome drugs?
- How many Opioid Withdrawal Syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Withdrawal Syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Withdrawal Syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Opioid Withdrawal Syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chiesi Farmaceutici S.p.A.
- BioXcel Therapeutics
- Aphios Pharmaceutical
- CHF6563
- BXCL501
- APH1501
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Opioid Withdrawal Syndrome: Overview
- ● Causes
- ● Mechanism of Action
- ● Signs and Symptoms
- ● Diagnosis
- ● Disease Management
- Pipeline Therapeutics
- ● Comparative Analysis
- Therapeutic Assessment
- ● Assessment by Product Type
- ● Assessment by Stage and Product Type
- ● Assessment by Route of Administration
- ● Assessment by Stage and Route of Administration
- ● Assessment by Molecule Type
- ● Assessment by Stage and Molecule Type
- Opioid Withdrawal Syndrome – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- ● Opioid Withdrawal Syndrome companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Opioid Withdrawal Syndrome Collaboration Deals
- ● Company-Company Collaborations (Licensing / Partnering) Analysis
- ● Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- ● Comparative Analysis
- Drug Name: Company Name
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ● Comparative Analysis
- CHF-6563: Chiesi Farmaceutici S.p.A.
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- ● Comparative Analysis
- BXCL501: BioXcel Therapeutics
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- ● Comparative Analysis
- Opioid Withdrawal Syndrome Key Companies
- Opioid Withdrawal Syndrome Key Products
- Opioid Withdrawal Syndrome- Unmet Needs
- Opioid Withdrawal Syndrome- Market Drivers and Barriers
- Opioid Withdrawal Syndrome- Future Perspectives and Conclusion
- Opioid Withdrawal Syndrome Analyst Views
- Opioid Withdrawal Syndrome Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.